Positron Emission Tomography(PET) in Lymphoma Assessment

Group A: Newly Diagnosed

Inclusion Criteria:

• Patients > 18 years of age.
• Confirmed diagnosis of HL or NHL (any histology).
• Any Ann Arbor stage.
• Pre-treatment staging including CT of head and neck, chest, abdomen and pelvis, where there is a minimum one equivocal finding on the scan, affecting the assignment of stage or IPI factor (i.e. stage III/IV vs. stage I/II, or a question of extranodal involvement by disease).

Group B: Response Assessment

Inclusion Criteria:

• Patients > 18 years of age.
• Confirmed diagnosis of HL or NHL (any histology).
• Any Ann Arbor stage.
• Pre-treatment staging including CT neck, chest, abdomen and pelvis. If alternate assessment of the neck done by clinical palpitation, ultrasound, or MRI is negative, CT neck is not mandatory.
• Post-treatment staging including CT of head and neck, chest, abdomen and pelvis, at 1 - 6 weeks post-therapy.
• Treated with anthracycline-based chemotherapy, with or without radiation therapy (based on the stage of the disease). For Stage III/IV patients, PET will be done following completion of primary chemotherapy. For stage I/II patients, PET will be done after combined modality therapy, or after chemotherapy alone if this was the primary intention of therapy.
• Patients with residual mass on CT following primary chemotherapy with either "unconfirmed" CR (>75% decrease in size) or PR (³50% decrease in size), based on International workshop criteria.

Exclusion Criteria: Response Assessment

• None Curative treatment Intent
• After initial therapy the response status is: complete response, stable disease, or progressive disease